Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison-Reference-Cited by-同舟云学术

Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison

Published:2023-10 Issue: Volume:144 Page:105485
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Machado Fernanda Lacerda da Silva,Cañás Martín,Doubova Svetlana V.,Urtasun Martín A.,Marín Gustavo H.,Osorio-de-Castro Claudia Garcia Serpa,Albuquerque Flavia Caixeta,Ribeiro Tatiane Bonfim,Pont Lisa,Crisóstomo Landeros José,Roldán Saelzer Juan,Sepúlveda Viveros Dino,Acosta Angela,Machado Beltrán Manuel A.,Gordillo Alas Lily Iracema,Orellana Tablas Lourdes Abigail,Benko Ria,Convertino Irma,Bonaso Marco,Tuccori Marco,Kirchmayer Ursula,Contreras Sánchez Saúl E.,Rodríguez-Tanta L. Yesenia,Gutierrez Aures Ysabel,Lin Boya,Alipour-Haris Golnoosh,Eworuke Efe,Lopes Luciane Cruz^ORCID

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference40 articles.

1. Real-world budget impact of the adoption of insulin glargine biosimilars in primary care in England (2015-2018);Agirrezabal;Diabetes Care,2020

2. Biosimilar Medicines Regulation,2018

3. Regulatory information and guidance on biosimilars and their use across Europe: a call for strengthened one voice messaging;Barbier;Front. Med.,2022

4. The impact of introducing successive biosimilars on changes in prices of adalimumab, infliximab, and trastuzumab—polish experiences;Barszczewska;Int. J. Environ. Res. Publ. Health,2021

5. Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades;Büssgen;BMC Health Serv. Res.,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献